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Abstract: Wegener’s granulomatosis (WG) is one of the most common small- and medium-sized necrotizing vasculitides 
that mainly affects the upper and lower respiratory tract and the kidneys. Cardiac manifestations in WG are relatively rare, 
and their role and place among different causes of mortality remain largely unknown. Substantially increased number of 
reports describing involvement of all structures of the heart, which underlie conduction disturbances, valvular disease, 
ischemic heart disease and other potentially serious conditions, underscores importance of comprehensive cardiovascular 
investigations  and  monitoring  of  patients  with  WG.  The  majority  of  previous  reports  and  our  current  observation  
distinguish  coronary  vasculitis  and  thrombosis  as  a  cause  of  myocardial  ischemia  and  cardiovascular  co-morbidities  
in WG. It seems plausible that inflammatory processes in this disease, like in some other systemic vasculitidies, do not 
predispose to accelerated atherogenesis. However, characteristic small- and medium-sized vasculitis still can manifest as 
myocardial ischemia and infarction. We overview diverse cardiac manifestations and present our own rare case of angina 
in the oligosymptomatic debut of WG. Importantly, in this case, coronarography failed to reveal atherosclerotic disease or 
thrombotic  occlusion.  However,  magnetic  resonance  imaging  (MRI)  with  adenosine  test  revealed  subendocardial  
ischemia.  As  a  result  of  immunosuppressive  therapy  with  a  steroid  and  cyclophosphamide,  myocardial  ischemia  
disappeared. 
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INTRODUCTION 
  In recent years, evidence has accumulated to suggest the 
crucial role of systemic inflammation and immune dysregu-
lation in enhanced cardiovascular morbidity and mortality in 
a variety of chronic inflammatory disorders [1-7]. Overex-
pression of common inflammatory, thrombotic and immune 
markers  alongside  with  active  contribution  of  disease-
specific  factors  form  pathophysiological  basis  for  diverse 
cardiovascular manifestations: pericarditis, myocarditis, car-
diomyopathy,  endocarditis,  valvular  disease,  coronaritis, 
aneurysms,  thrombosis  and  atherosclerotic  cardiovascular 
disease, pulmonary and systemic hypertension, rhythm and 
conduction disturbances, diastolic and systolic heart failure 
[1, 8-10]. Moreover, it has been well established that addi-
tive  effect  of  classical  cardiovascular  risk  factors,  such  as 
smoking, hypertension, dyslipidemia, diabetes, physical in-
activity,  may  substantially  increase  the  risk  of  vascular 
events  in  inflammatory  disorders,  particularly  in  systemic 
lupus erythematosus (SLE) and rheumatoid arthritis (RA) [3, 
6, 11-13]. Another important factor increasing cardiovascu-
lar  risk  is  a  prolonged  severe  course  of  an  underlying  
inflammatory  condition  and  associated  long-term  therapy 
with  high  dose  steroids,  which  mediate  negative  vascular  
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effects  through  steroid-induced  diabetes,  hypertension, 
atherogenic lipid disturbances and obesity [14-19]. 
  Predisposing factors, morphological changes and clinical 
manifestations of inflammation-induced cardiovascular mor-
bidity and mortality are relatively well investigated in SLE 
and RA. Though cardiovascular  comorbidities in SLE  and 
RA  are  not  limited  to  ischemic  heart  disease  (IHD),  both 
inflammatory  disorders  can  be  viewed  as  models  of  en-
hanced coronary atherogenesis, based on the results of mul-
tiple epidemiological, vascular imaging, clinicopathological 
and pathomorphological studies [20-25]. Importance of these 
results is difficult to overestimate, especially given the car-
diovascular  perspectives  of  anti-inflammatory  preventive 
measures in the general population. Remarkable example, in 
this  regard,  is  a  recent  attempt  to  reduce  cardiovascular 
events in a large population of patients with stable IHD and 
subclinical  inflammation  with  the  use  of  low  dose 
methotrexate therapy, a first-line drug therapy for RA, in the 
Cardiovascular Inflammation  Reduction Trial (CIRT) [26]. 
Positive  results  of  this  trial  will  provide  strong  evidence  
for inflammatory hypothesis of atherogenesis and pave way 
for  the  use  of  other  safe  anti-inflammatory  drugs  in  low-
grade inflammatory disease states associated with increased 
vascular risk. 
  To  better  understand  implications  of  inflammation  in 
atherogenesis, apart from SLE and RA, cardiovascular mani-
festations of seemingly  less atherogenic disorders,  such as 58    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Cocco and Gasparyan 
primary  small-  and  medium-sized  systemic  vasculitides 
(Wegener’s granulomatosis [WG], polyarteritis nodosa, Ka-
wasaki  disease,  Churg-Strauss  syndrome,  and  microscopic 
polyangiitis),  should  be  further  investigated.  Though  these 
disorders are associated with overexpression of multiple in-
flammatory markers, which cause endothelial damage, there 
is no direct evidence to categorize them as pro-atherogenic 
states  [27-30].  Differences  in  atherogenic  profiles  in  SLE, 
RA and primary vasculitides may be linked to the intensity 
of systemic  inflammation, preferential  involvement of dis-
ease  specific  markers,  differing  in  atherogenic  properties, 
and genetic markers with different vasculopathic targets [31, 
32].  To  further  elucidate  mechanisms  of  vasculopathy  in 
systemic vasculitides comprehensive investigation of clinical 
manifestations  of  cardiovascular  involvement  and  multina-
tional database of case reports on different types of cardio-
vascular pathology in each systemic vasculitis are urgently 
needed. We hereby overview cardiovascular manifestations 
in WG and analyze own case report. 
CARDIAC  MANIFESTATIONS  IN  WEGENER’S 
GRANULOMATOSIS 
  WG is one of the most common necrotizing vasculitides. 
The  prevalence  of  the  disease  is  3  in  100,000  population 
with male to female ratio of 3:2, and peak incidence at the 
age of 50-60 [33]. Etiology still remains unknown. Granu-
lomatous lesions of the upper and lower airways and the kid-
neys are predominant features of the disease [34, 35]. Classi-
cal  clinical  presentation  of  WG  includes  ear,  nose,  throat 
(ENT)  involvement,  saddle-nose  deformity  due  to  the  de-
struction of the nasal septum, epistaxis, nasal crusting and 
sinusitis, pulmonary involvement with hemoptysis (alveolar 
hemorrhage and capillaritis), cough and dyspnea, arthralgia, 
optic neuritis, peripheral neuropathy, and necrotizing glome-
rulonephritis [33, 35]. 
  It has long been known that kidney and lung affections 
are major predictors of mortality, and cardiac involvement  
is  relatively  infrequent  in  WG  [35].  In  one  cohort  of  158 
patients  with  WG,  cardiac  manifestations  (predominantly 
pericarditis) were present in 10 patients (6%), and, of these, 
3  patients  had  coronary  artery  involvement  [36,  37].  The  
results of autopsy, however, demonstrated that  cardiac  ab-
normalities can be present in one third of patients with WG 
who have no clinical signs of cardiac pathology and die pre-
dominantly from non-cardiac causes [33]. 
  In a multiple series of recent observations, clinical sig-
nificance and potentially lethal consequences of diverse car-
diac affections have been recognized. In fact, numerous re-
ports on WG with conduction disturbances, such as complete 
heart block due to inflammation of atrioventricular node, and 
arrhythmias  with  compromised  hemodynamics  have  been 
published  over  the  past  decade  [38-43].  Pericarditis,  coro-
naritis,  focal  myocarditis,  cardiomyopathy,  noninfectious 
endocarditis,  valvular  disease  with  vegetations,  mitral  and 
aortal insufficiency, and systolic heart failure are other fre-
quently reported cardiac manifestations in WG [1, 44-48]. 
  It should be noted that histopathological changes under-
lying systemic affections in WG occur in the absence of im-
mune deposits, and include neutrophilic vasculitis, necrosis, 
microabscesses  and  granuloma  [35].  These  changes  are 
driven by highly specific for WG antineutrophil cytoplasmic 
antibodies (ANCA) directed against cytoplasmic compound, 
proteinase-3  (cANCA).  Anti-proteinase-3  antibodies  cause 
degranulation of neutrophils with subsequent release of pro-
teolytic enzymes, damaging the endothelium and triggering 
vasculopathic cascade [8, 49]. Though it is well-known that 
endothelial dysfunction due to small vessel disease is charac-
teristic  for  WG  [50],  recently  published  reports,  mainly 
based on the newest imaging techniques, point to the possi-
bility of systemic involvement of larger size vessels, result-
ing in arterial aneurysms and venous thrombosis [51-57]. 
  In  the  most  cases  of  WG,  atherosclerotic  vascular  dis-
ease,  particularly  that  seen  in  SLE  and  RA,  has  not  been 
documented, reflecting the fact that vascular  inflammation 
and thrombosis, including  coronaritis  and coronary  throm-
boembolism, as  more  characteristic for WG [1, 58-60]. In 
contrary, in a small case-control study, an increase of intima-
media  thickness  (IMT)  of  the  carotid  artery  was  found  in 
patients with WG, interpreted as a sign of accelerated athero-
sclerosis [61]. The results of this observation, however, need 
further confirmation in a long-term studies with better de-
fined markers of atherosclerosis (e.g. carotid plaques, angi-
ographically  and  pathomorphologically  confirmed  athero-
sclerotic lesions), since an increase of IMT in a chronic in-
flammatory disorder can be merely a reflection of inflamma-
tion in the vessel wall, but not atherosclerosis [62]. 
  Whatever the underlying mechanism of coronary pathol-
ogy, in a large cohort of patients with WG, a significantly 
increased  risk  of  IHD  was  recently  reported  (observed  to 
expected ratio of IHD events 1.9, 95% confidence interval 
[95%CI] 1.4-2.4) [63]. An increased risk of IHD was largely 
due to the relatively high incidence of myocardial infarction 
(MI), particularly in those with advanced age at the time of 
diagnosis, in males, and in those treated with high doses of 
cyclophosphamide. This study confirmed the results of pre-
vious  reports,  indicating  that  patients  with  WG  frequently 
experience ‘silent’ IHD [64,65], which may further contrib-
ute to an increase of mortality rates. 
  Multiple  series  of  case  reports  and  cohort  studies  ana-
lyzed above highlight importance of comprehensive cardio-
vascular assessment of patients with WG even in clinically 
asymptomatic cases. It should be also kept in mind that car-
diovascular manifestations (e.g. conduction block, MI, heart 
failure) can evolve in  the  absence of  classical  complex of 
symptoms or in so called ‘limited WG’. We hereby present a 
rare case of angina in the debut of WG, in the absence of 
classical cardiovascular risk factors. 
CASE PRESENTATION 
  A 64-year-old woman was admitted to the hospital with 
angina (CCS II) and signs of heart failure (NYHA III) of two 
weeks duration. She was examined four weeks prior to the 
admission. At that time only pain on palpation and symmet-
rical  swelling  of  her  hands  were  noticed.  Diclofenac  was 
administered. The patient had a flu-like illness three months 
ago, which followed by fatigue, malaise, arthralgia, myalgia, 
orthostatic dizziness, and morning stiffness. The symptoms 
improved in response to oral diclofenac. 
  On physical examination, there was tenderness of wrists 
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2/6 grade systolic murmur was audible over the all ausculta-
tion points. There were no hepatosplenomegaly, lymphade-
nopathy. 
  Importantly, on ECG, there were ST-T changes in I, aVL 
and V3-6 (Fig. 1). Except for localized pericardial thicken-
ing, echocardiography did not reveal any other pathological 
changes. Abdominal ultrasound and computed  tomography 
(CT) did not reveal pathological changes. 
  Blood  tests:  erythrocyte  sedimentation  rate  (ESR)  90 
mm/hour, C reactive protein (CRP) 16.5 mg/L (normal range 
<9 mg/L), hemoglobin 10.8 g/dL, white blood  cells 7,450 
per  microliter,  platelets  434,000  per  microliter.  Liver  and 
kidney function tests were within normal limits. Urinalysis 
was without pathological findings. 
  Test for HIV was negative. Multiple series of blood and 
urine culture tests were negative. 
  Antistreptolysin  O  titer  was  1:400  (normal  range 
<1:300), rheumatoid factor - positive, antinuclear antibodies 
and the Coomb’s test - negative. An enzyme-linked immu-
nosorbent assay was positive for cANCA (43; normal range 
<20). 
  On the 3
rd day, the patient presented with fever, shortness 
of breath, paresthesia in both hands and feet. On neurologi-
cal  examination,  symmetrical  peripheral  neuropathy  was 
noted. Chest radiography showed infiltrate in the right lower 
lobe. 
  On the 6
th day, dyspnea became severe. Arterial partial 
pressure of O2 (PO2) was 50 mmHg, carbon dioxide (PCO2) 
32 mmHg, bicarbonate level 21 mmol/L, O2 saturation 86 %, 
pH, 7.42. On chest X-ray, pulmonary infiltrates disseminated 
in  both  lungs.  Bronchoscopy  with  bronchoalveolar  lavage 
fluid  examination  revealed  multiple  erythrocytes;  tests  for 
Pneumocystis carinii and Mycobacteria were negative. Lung 
biopsy revealed alveolar hemorrhage. 
  On  the  7
th  day,  erythematous  rash  erupted,  and  skin  
biopsy performed from the affected area revealed leukocyto-
clastic vasculitis. 
  CT of paranasal sinuses was performed, which revealed 
thickening of the mucous membrane of the left frontal and 
right maxillary sinuses. Biopsy from the inferior concha was 
suggestive of nonspecific inflammation. 
  A  bone  marrow  biopsy  revealed  mild  eosinophilia  and 
plasmocytosis, and otherwise was unremarkable. An open-
lung biopsy revealed histological signs of neutrophilic mi-
croabscesses, thrombosis, hemorrhage and granuloma char-
acteristic for WG with palisading histiocytes, CD3+ T cells, 
CD68+  histiocytes,  histiocytic  giant  cells,  eosinophils  and 
CD20+ B cells. 
  The patient was initially treated with combination of ce-
furoxime, gentamycine and erythromycine. After the diagno-
sis of WG was made, intravenous methylprednisolone (500 
mg daily) and oral cyclophosphamide (300 mg daily) were 
initiated. 
  On  the  12
th  day,  cardiac  MRI  was  performed  (Fig.  2), 
which showed only mild cardiomegaly with preserved sys-
tolic  function  (left  ventricular  ejection  fraction  [EF]  78%) 
and absence of valvular abnormalities. The aorta and both 
ventricles were without pathological changes (no signs of old 
MI). Adenosine infusion, however, revealed subendocardial 
perfusion  defects  especially  expressed  in  the  septum  and 
posterior wall of the left ventricle. 
  On  ventriculocoronarography,  global  contractility  was 
not impaired, left ventricular EF was 78%, apex and lateral 
wall of the left ventricle were unusually rounded; no signs of 
valvular  pathology;  except  from  minor  sclerotic  changes, 
coronary arteries were otherwise unchanged (Fig. 3). 
  The patient was discharged on the 20
th day with recom-












Fig. (1). ECG on admission. Regular sinus rhythm, heart axis deviation to the left, ST-T changes of ischemic origin in I, aVL and V3-6. 60    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Cocco and Gasparyan 
mg daily). Six weeks  after  the discharge, dyspnea, angina 
and  initially  recorded  ischemic  changes  on  ECG  disap-
peared, and repeated stress test with adenosine did not show 
perfusion defects. Renal function tests were within normal 
limits. Inflammation of paranasal sinuses resolved. Repeated 
chest CT, performed after 6 months, documented absence of 
pulmonary  infiltrates.  Sixteen  months  after  the  discharge, 
vision loss and peripheral neuropathy were residual signs of 
WG. Cyclophosphamide switched to azathioprine, and pred-
nisone maintenance dose remained at 10 mg daily. 
  A  year  later,  the  patient  developed  hypertension 
(>160/100  mmHg),  which  responded  to  antihypertensive 














Fig.  (2).  Magnetic  resonance  imaging  (MRI).  Ascending  and  thoracic  aorta  (A),  both  ventricles  of  the  heart  (B)  without  pathological 













Fig. (3). Coronaroangiography. Left (A, B) and right coronary arteries (B, C, D) without visible pathological changes. Myocardial Ischemia in Wegener’s Granulomatosis  The Open Cardiovascular Medicine Journal, 2010, Volume 4    61 
tor and angiotensin II receptor blocker, and the decision was 
made to start antiplatelet therapy (clopidogrel 75 mg daily) 
on top of immunosuppressive  therapy with prednisone 7.5 
mg daily and azathioprine 50 mg two times daily. Repeated 
cANCA test at that time was still positive (28), ESR was 35 
mm/hour, CRP 12 mg/L.  
DISCUSSION 
  Multisystemic  affections  gradually  evolving  in  this  pa-
tient were suggestive of WG. The diagnosis, primarily based 
on the presence of pulmonary infiltrates and biopsy findings, 
was in accordance with the American College of Rheuma-
tology (ACR) classification criteria of WG [66]. The latter 
requires  presence  of  at  least  2  out  of  4  criteria:  abnormal 
urinary sediment, abnormal chest radiograph (nodules, cavi-
ties, or infiltrates), oral ulcers or nasal discharge, and charac-
teristic biopsy findings. In our patient, initial diagnostic con-
fusion  was  due  to  oligosymptomatic  presentation  (limited 
WG) with angina and signs of heart failure. The diagnosis of 
WG was further supported by positive cANCA test and bi-
opsy suggestive of granulomatous vasculitis. Our case once 
again underscores the fact that WG can present with myo-
cardial ischemia due to coronary vasculitis [67]. Previously 
reported cases of coronary artery involvement in WG failed 
to document clinically significant atherosclerotic disease and 
proved that myocardial ischemia in WG is mainly due to the 
occlusion of small-  and medium-sized  coronary arteries at 
the cardiac apex [67]. In our case, MRI with adenosine test 
detected transient subendocardial ischemia in the septum and 
posterior wall of the left ventricle, which coupled with coro-
nary  angiography  (no  visible  changes)  and  ECG  findings 
(ischemic changes of ST-T), distinguished small vessel dis-
ease  as  a  cause  of  angina.  Importantly,  angina  and  ECG 
changes disappeared in response to the treatment with steroid 
and cyclophosphamide, which can be viewed as another fact 
in favor of vasculitic origin of microcoronary abnormalities. 
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